Colchicine for the Treatment of Osteoarthritis of the Knee (CLOAK)
A Phase IV, Randomized, Double-Blind, Placebo-Controlled, Single-Center Study of the Effects of Colchicine on Pain and Inflammation in Subjects With Knee Osteoarthritis
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 4
Contacts and Locations
Study Contact
Study Contact
- Name: Katherine Tse
- Phone Number: 646-501-7388
- Email: Katherine.tse@nyulangone.org
Study Locations
-
-
New York
-
New York, New York, United States, 10016
- NYU Langone Health
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Are 40 years old or older
- Continue to experience frequent knee symptoms as defined above
- Have KL grade 2 or 3 on their last knee radiograph done for the parent study
- Have an estimated glomerular filtration rate (eGFR) > 30 ml/min (MDRD equation) and liver transaminases < 2x the upper limit of normal
- Have a BMI ≤ 32 at the time of enrollment
- Agree to be randomized to take colchicine or placebo daily for 3 months
Exclusion Criteria:
- Have received hyaluronic acid or corticosteroid steroid injection within the past 3 months
- Have a diagnosis of gout/pseudogout or other inflammatory arthritis (rheumatoid arthritis, psoriatic arthritis, reactive arthritis, spondyloarthropathy etc).
- Have a diagnosis of diabetes mellitus, chronic infectious disease, congestive heart failure, non-cutaneous cancer within the past 5 years
- Plan on undergoing total knee replacement within the next 3 months
- Be using any medication that is a strong CYP3A4 inhibitor whose metabolism may interact with colchicine (e.g., certain protease inhibitors, certain azole antifungal agents, clarithromycin).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Placebo Comparator: Placebo
Placebo in capsule identical to study drug
|
Placebo 0.8 mg or 0.6 mg orally once daily for 3 months
|
|
Experimental: Colchicine
0.6 or 0.8 mg orally once daily. Because recent studies suggest that a dose of 0.6mg may be sufficient for chronic inflammatory suppression and may reduce the already low risk of toxicity of 0.8mg, for the remainder (second half) of the study the dosage will be switched from 0.8mg to a 0.6mg dose to allow comparison of the two doses. |
Colchicine 0.8 mg orally once daily for 1.5 months, and then 0.6 mg once daily for the remainder of the time (1.5 months)
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in Visual Analog Scale (VAS) Pain Score
Time Frame: Baseline, 3 Months
|
VAS is a tool widely used to measure pain.
A patient is asked to indicate his/her perceived pain intensity (most commonly) along a 10 mm horizontal line, and this rating is then measured from the left edge (=VAS score).
The total score range is 0 (no pain) to 10 (worst pain imaginable); the higher the score, the worse the pain.
|
Baseline, 3 Months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in the Knee Injury and Osteoarthritis Outcome Score (KOOS) Pain Score
Time Frame: Baseline, 3 Months
|
The KOOS survey is comprised of 42 questions.
The questions are divided into 5 sub-categories: symptoms/stiffness (7 questions), pain (9 questions), function/daily living (17 questions), function/sports and recreational activities (5 questions), and quality of life (4 questions).
The KOOS Pain Score refers to a specific subscale within the KOOS questionnaire that measures the severity of knee pain experienced by a patient, consisting of nine questions where each response is scored on a scale from 0 (no pain) to 4 (extreme pain), with a higher score indicating greater pain intensity; the overall pain score is then calculated as a percentage of the maximum possible score, where 0 represents the worst possible pain and 100 represents no pain at all.
|
Baseline, 3 Months
|
|
Change in the KOOS Stiffness Score
Time Frame: Baseline, 3 Months
|
The KOOS survey is comprised of 42 questions.
The questions are divided into 5 sub-categories: symptoms/stiffness (7 questions), pain (9 questions), function/daily living (17 questions), function/sports and recreational activities (5 questions), and quality of life (4 questions).
Each item on the KOOS is scored on a scale from 0 (no problems) to 4 (extreme problems), and then the scores are calculated to generate a final score between 0 and 100.
The KOOS stiffness score is a percentage from 0 to 100 that measures how much stiffness a patient experiences in their knee.
A score of 0 indicates the most stiffness, while a score of 100 indicates no stiffness.
|
Baseline, 3 Months
|
|
Change in the KOOS Physical Function Score
Time Frame: Baseline, 3 Months
|
The KOOS's five patient-relevant dimensions are scored separately: Pain (9 items); Symptoms/Stiffness (7 items); Function, Daily Living (17 items); Function, Sports and Recreational Activities (5 items); Quality of Life (4 items).
The KOOS Physical Function items are scored on a Likert scale from 0 to 4, with 0 indicating no problems and 4 indicating extreme problems.
The scores for each dimension are then transformed to a scale from 0 to 100, where 0 represents extreme problems with knee function and 100 indicates no problems at all.
|
Baseline, 3 Months
|
|
Change in the KOOS Quality of Life Score
Time Frame: Baseline, 3 Months
|
The KOOS survey is comprised of 42 questions.
The questions are divided into 5 sub-categories: symptoms/stiffness (7 questions), pain (9 questions), function/daily living (17 questions), function/sports and recreational activities (5 questions), and quality of life (4 questions).
A KOOS Quality of Life score ranges from 0 to 100, where 0 represents the worst possible knee-related quality of life and 100 indicates no problems at all.
A higher score indicates better quality of life related to the knee.
|
Baseline, 3 Months
|
|
Change in the KOOS Sports and Recreational Activities
Time Frame: Baseline, 3 Months
|
The KOOS's five patient-relevant dimensions are scored separately: Pain (9 items); Symptoms/Stiffness (7 items); Function, Daily Living (17 items); Function, Sports and Recreational Activities (5 items); Quality of Life (4 items).
The KOOS Sports and Recreational Activities 9 items are scored on a Likert scale from 0 to 4, with 0 indicating no problems and 4 indicating extreme problems relating to sports and recreational activities.
The scores are then transformed to a scale from 0 to 100, with 100 indicating no knee problems with sports and recreational activities and 0 indicating extreme knee problems with sports and recreational activities .
|
Baseline, 3 Months
|
|
Change in the KOOS Total Score
Time Frame: Baseline, 3 Months
|
The KOOS survey is comprised of 42 questions.
The questions are divided into 5 sub-categories: symptoms/stiffness (7 questions), pain (9 questions), function/daily living (17 questions), function/sports and recreational activities (5 questions), and quality of life (4 questions).
The total range for each sub-category is 0-100, making the total range for the whole survey 0-500.
The higher the score, the worse the symptoms and pain/ higher difficulty in function.
|
Baseline, 3 Months
|
|
Number of Participants Who Used Acetaminophen or Other Medications for Pain
Time Frame: 6 weeks
|
6 weeks
|
|
|
Number of Participants Who Used Acetaminophen or Other Medications for Pain
Time Frame: 3 Months
|
3 Months
|
|
|
Change in Number of Participants Who Used Acetaminophen or Other Medications for Pain
Time Frame: 6 weeks, 3 months
|
6 weeks, 3 months
|
|
|
Change in Inflammatory Plasma Marker: Interleukin-1 Receptor Antagonist (IL-1Ra)
Time Frame: Baseline, 3 months
|
Baseline, 3 months
|
|
|
Change in Inflammatory Plasma Marker: Prostaglandin E2 (PGE2)
Time Frame: Baseline, 3 months
|
Baseline, 3 months
|
|
|
Change in Musculoskeletal Ultrasound (MSK-US)-Measured Effusion
Time Frame: Baseline, 3 months
|
Size of effusion is measured as millimeters
|
Baseline, 3 months
|
|
Change in Rates of Crystal Deposition (Urate, Calcium) on MSK-US
Time Frame: Baseline, 3 months
|
Baseline, 3 months
|
|
|
Change in Inflammatory Plasma Marker: Highly Sensitive C-reactive Protein (hsCRP)
Time Frame: Baseline, 3 months
|
Baseline, 3 months
|
|
|
Change in Inflammatory Plasma Marker: Uric Acid
Time Frame: Baseline, 3 months
|
Baseline, 3 months
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Michael H Pillinger, MD, FACP, NYU Langone Health
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 16-01796
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.